What we’re doing
We are pleased to announce the approval of non-exclusive listing agreements with LifeHealthcare Limited (“LifeHealthcare”) and Surgical Innovations Limited (“Surgical Innovations”) for the supply of orthopaedic implants and associated products (“Orthopaedic Products”).
In summary, this will result in LifeHealthcare and Surgical Innovations ranges of Orthopaedic Products being listed in Part III of Section H of the Pharmaceutical Schedule from 1 April 2020.
DHBs will be able to continue to purchase other suppliers’ brands of Orthopaedic Products as the agreements are not for sole supply.
Detail about this decision
In April 2016 PHARMAC issued a request for proposals (“RFP”) for orthopaedic implants and associated products. The RFP requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
After evaluating LifeHealthcare’s and Surgical Innovation’s proposals and consulting on the provisional agreements reached with them, PHARMAC has decided to list LifeHealthcare’s and Surgical Innovation’s ranges of Orthopaedic Products in Part III of Section H of the Pharmaceutical Schedule from 1 April 2020.
These two agreements are the final agreements that will be entered into in the orthopaedic products category as a result of the RFP.
The following product ranges and brands are included in the agreements:
Anterior Spine Truss,Cervical Spine Truss, Posterior Spine Truss
EIT Smart Spinal
Distal joint and Trauma implants
Surgical bone cements and Allografts
Our response to what you told us
We appreciate the time people took to respond to this consultation.
All consultation responses received by 13 February 2020 and 25 February 2020, respectively, were considered in their entirety in making the decision to approve each agreement.
A summary of the main themes raised in feedback and our responses to the feedback are set out below:
|LifeHealthcare and Surgical Innovations|
|No technical or resource impacts are exected as a result of the proposals||Noted|
|Savings opportunity noted||Noted|
If you have any questions about this decision, you can email us at email@example.com; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.
Last updated: 3 March 2020